Drug Makers And Payers To Blame For Biosimilar Barriers In U.S. MarketBy Press Room4 September 2025 If there is one thing that all stakeholders in the prescription drug supply chain can agree on it’s that patients’…
Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy RideBy Press Room4 November 2024 Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making inroads in…